Family · Pharmaceutical analytical standards
Ertugliflozin
An SGLT2 inhibitor (gliflozin) for type 2 diabetes, approved in the United States at the end of 2017: it makes the body pass some excess sugar in the urine by blocking its reabsorption in the kidneys. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?Its 'sugar' part is not a simple ring: an extra bridge locks it into a rigid bicyclic cage, unusual among gliflozins. It blocks SGLT2 more than 2000 times more strongly than SGLT1.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
